Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?

ABSTRACT: Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis, venous thromboembolic events (VTEs), and arterial thrombosis. This literature review examines studies reporting the risk of VTEs associated with JAKis in patients with inflammatory diseases. Phase I to III trials showed no increased risk of VTEs. However, these studies were not designed to detect adverse events such as VTEs. The pharmacovigilance data indicated that the frequency of VTE reports was higher than that of other adverse events. An increased risk of VTEs was also observed in the ORAL Surveillance study, a randomized, noninferior

SUBMITTER: Dawudi Y 

PROVIDER: S-EPMC11840193 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature